Review



bayk 8644  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Tocris bayk 8644
    Bayk 8644, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bayk 8644/product/Tocris
    Average 94 stars, based on 70 article reviews
    bayk 8644 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    bay k 8644 bayk alomone labs b 351 50 mm in dmso  (Alomone Labs)
    90
    Alomone Labs bay k 8644 bayk alomone labs b 351 50 mm in dmso
    Bay K 8644 Bayk Alomone Labs B 351 50 Mm In Dmso, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bay k 8644 bayk alomone labs b 351 50 mm in dmso/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    bay k 8644 bayk alomone labs b 351 50 mm in dmso - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bayk 8644  (Tocris)
    94
    Tocris bayk 8644
    Bayk 8644, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bayk 8644/product/Tocris
    Average 94 stars, based on 1 article reviews
    bayk 8644 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    bayk-8644  (Tocris)
    90
    Tocris bayk-8644
    Bayk 8644, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bayk-8644/product/Tocris
    Average 90 stars, based on 1 article reviews
    bayk-8644 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bayk  (MedChemExpress)
    94
    MedChemExpress bayk
    Brn3a-labeled RGCs in control, DM and different drug-treated retinas (A1–C3) Fluorescence micrographs from the peripheral, middle and central regions in flat-mount retinas showing Brn3a-labeled surviving RGCs in normal (A1–C1), DM eyes treated with (A3–C3) or without saline (A2–C2). (A4–C7) Fluorescence micrographs from the peripheral, middle and central regions in flat-mounted retinas depicting Brn3a-labeled RGCs in DM eyes treated with Ex-4 (A4–C4), Ex-9-39+Ex-4 (A5–C5), <t>BayK-8644</t> (A6–C6), or BayK-8644+Ex-4 (A7–C7). Topical administration of Ex-4 increased RGC viability in the peripheral and middle regions of the retinas (A4, B4). Administration of Ex-9-39 (A5, B5) or BayK-8644 (A7, B7) blocked the protective effects of Ex-4 on RGCs. Scale bar: 50 μm.
    Bayk, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bayk/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    bayk - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    bayk 8644 (tocris cat#1546)  (Tocris)
    90
    Tocris bayk 8644 (tocris cat#1546)
    Brn3a-labeled RGCs in control, DM and different drug-treated retinas (A1–C3) Fluorescence micrographs from the peripheral, middle and central regions in flat-mount retinas showing Brn3a-labeled surviving RGCs in normal (A1–C1), DM eyes treated with (A3–C3) or without saline (A2–C2). (A4–C7) Fluorescence micrographs from the peripheral, middle and central regions in flat-mounted retinas depicting Brn3a-labeled RGCs in DM eyes treated with Ex-4 (A4–C4), Ex-9-39+Ex-4 (A5–C5), <t>BayK-8644</t> (A6–C6), or BayK-8644+Ex-4 (A7–C7). Topical administration of Ex-4 increased RGC viability in the peripheral and middle regions of the retinas (A4, B4). Administration of Ex-9-39 (A5, B5) or BayK-8644 (A7, B7) blocked the protective effects of Ex-4 on RGCs. Scale bar: 50 μm.
    Bayk 8644 (Tocris Cat#1546), supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bayk 8644 (tocris cat#1546)/product/Tocris
    Average 90 stars, based on 1 article reviews
    bayk 8644 (tocris cat#1546) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bayk 8644 tocris cat#1546  (Tocris)
    90
    Tocris bayk 8644 tocris cat#1546
    Brn3a-labeled RGCs in control, DM and different drug-treated retinas (A1–C3) Fluorescence micrographs from the peripheral, middle and central regions in flat-mount retinas showing Brn3a-labeled surviving RGCs in normal (A1–C1), DM eyes treated with (A3–C3) or without saline (A2–C2). (A4–C7) Fluorescence micrographs from the peripheral, middle and central regions in flat-mounted retinas depicting Brn3a-labeled RGCs in DM eyes treated with Ex-4 (A4–C4), Ex-9-39+Ex-4 (A5–C5), <t>BayK-8644</t> (A6–C6), or BayK-8644+Ex-4 (A7–C7). Topical administration of Ex-4 increased RGC viability in the peripheral and middle regions of the retinas (A4, B4). Administration of Ex-9-39 (A5, B5) or BayK-8644 (A7, B7) blocked the protective effects of Ex-4 on RGCs. Scale bar: 50 μm.
    Bayk 8644 Tocris Cat#1546, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bayk 8644 tocris cat#1546/product/Tocris
    Average 90 stars, based on 1 article reviews
    bayk 8644 tocris cat#1546 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bayk-8644  (Axon Medchem LLC)
    90
    Axon Medchem LLC bayk-8644
    Brn3a-labeled RGCs in control, DM and different drug-treated retinas (A1–C3) Fluorescence micrographs from the peripheral, middle and central regions in flat-mount retinas showing Brn3a-labeled surviving RGCs in normal (A1–C1), DM eyes treated with (A3–C3) or without saline (A2–C2). (A4–C7) Fluorescence micrographs from the peripheral, middle and central regions in flat-mounted retinas depicting Brn3a-labeled RGCs in DM eyes treated with Ex-4 (A4–C4), Ex-9-39+Ex-4 (A5–C5), <t>BayK-8644</t> (A6–C6), or BayK-8644+Ex-4 (A7–C7). Topical administration of Ex-4 increased RGC viability in the peripheral and middle regions of the retinas (A4, B4). Administration of Ex-9-39 (A5, B5) or BayK-8644 (A7, B7) blocked the protective effects of Ex-4 on RGCs. Scale bar: 50 μm.
    Bayk 8644, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bayk-8644/product/Axon Medchem LLC
    Average 90 stars, based on 1 article reviews
    bayk-8644 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Brn3a-labeled RGCs in control, DM and different drug-treated retinas (A1–C3) Fluorescence micrographs from the peripheral, middle and central regions in flat-mount retinas showing Brn3a-labeled surviving RGCs in normal (A1–C1), DM eyes treated with (A3–C3) or without saline (A2–C2). (A4–C7) Fluorescence micrographs from the peripheral, middle and central regions in flat-mounted retinas depicting Brn3a-labeled RGCs in DM eyes treated with Ex-4 (A4–C4), Ex-9-39+Ex-4 (A5–C5), BayK-8644 (A6–C6), or BayK-8644+Ex-4 (A7–C7). Topical administration of Ex-4 increased RGC viability in the peripheral and middle regions of the retinas (A4, B4). Administration of Ex-9-39 (A5, B5) or BayK-8644 (A7, B7) blocked the protective effects of Ex-4 on RGCs. Scale bar: 50 μm.

    Journal: iScience

    Article Title: Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes

    doi: 10.1016/j.isci.2023.107680

    Figure Lengend Snippet: Brn3a-labeled RGCs in control, DM and different drug-treated retinas (A1–C3) Fluorescence micrographs from the peripheral, middle and central regions in flat-mount retinas showing Brn3a-labeled surviving RGCs in normal (A1–C1), DM eyes treated with (A3–C3) or without saline (A2–C2). (A4–C7) Fluorescence micrographs from the peripheral, middle and central regions in flat-mounted retinas depicting Brn3a-labeled RGCs in DM eyes treated with Ex-4 (A4–C4), Ex-9-39+Ex-4 (A5–C5), BayK-8644 (A6–C6), or BayK-8644+Ex-4 (A7–C7). Topical administration of Ex-4 increased RGC viability in the peripheral and middle regions of the retinas (A4, B4). Administration of Ex-9-39 (A5, B5) or BayK-8644 (A7, B7) blocked the protective effects of Ex-4 on RGCs. Scale bar: 50 μm.

    Article Snippet: Ex-4, nimodipine, Ex-9-39 and BayK-8644 were purchased from MedChemExpress (Monmouth Junction, NJ, USA), while TTX, Ryanodine, W-7 and U-73122 were from Tocris Bioscience (Ellisville, MO, USA).

    Techniques: Labeling, Fluorescence, Saline

    Quantitative analysis of the density of surviving RGCs (A–C) Schematic diagrams of flat-mount retinas, illustration of 12 areas of RGC quantification (4 peripheral, 4 middle and 4 central, indicated by green squares). (D–F) Quantitative analysis of the density of surviving RGCs in the peripheral (D), middle (E) and central regions (F) of retinas from control, DM eyes, saline-treated DM eyes, Ex-4-treated DM eyes, DM eyes treated with Ex-4+Ex-9-39, BayK-8644, or Ex-4+BayK-8644. Retina numbers are noted in the bars. Data are presented as mean ± SD, ∗p < 0.05, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001 vs. control; †p < 0.05 and †††p < 0.001 vs. DM + Saline by Tukey’s multiple comparisons test after one-way ANOVA.

    Journal: iScience

    Article Title: Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes

    doi: 10.1016/j.isci.2023.107680

    Figure Lengend Snippet: Quantitative analysis of the density of surviving RGCs (A–C) Schematic diagrams of flat-mount retinas, illustration of 12 areas of RGC quantification (4 peripheral, 4 middle and 4 central, indicated by green squares). (D–F) Quantitative analysis of the density of surviving RGCs in the peripheral (D), middle (E) and central regions (F) of retinas from control, DM eyes, saline-treated DM eyes, Ex-4-treated DM eyes, DM eyes treated with Ex-4+Ex-9-39, BayK-8644, or Ex-4+BayK-8644. Retina numbers are noted in the bars. Data are presented as mean ± SD, ∗p < 0.05, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001 vs. control; †p < 0.05 and †††p < 0.001 vs. DM + Saline by Tukey’s multiple comparisons test after one-way ANOVA.

    Article Snippet: Ex-4, nimodipine, Ex-9-39 and BayK-8644 were purchased from MedChemExpress (Monmouth Junction, NJ, USA), while TTX, Ryanodine, W-7 and U-73122 were from Tocris Bioscience (Ellisville, MO, USA).

    Techniques: Saline